REG - ConvaTec Group PLC - Scrip Dividend - Calculation Price

ConvaTecAnnouncement

12/09/2019 16:00

RNS Number : 1802M
ConvaTec Group PLC
12 September 2019
 


 
 
Scrip Dividend - calculation price
 
 
Reading, United Kingdom (12 September 2019)
On 31 July 2019 ConvaTec Group Plc ("ConvaTec" or "the Company") declared an interim dividend of 1.717 cents per share (the "interim dividend"). This interim dividend is to be paid on 17 October 2019 to shareholders on the share register as at 6 September 2019 ("record date"). The dividend is payable in cash in sterling to holders of ordinary shares, the chosen exchange rate for this payment is $1.223/£1.00, determined on 31 July 2019, giving a total sterling dividend of £27,760,563. On 1 August 2019 the Company announced that a scrip dividend will be made available for this interim dividend allowing shareholders to elect to receive their dividend in the form of new ordinary shares.
The "Calculation Price" for the issue of new ordinary shares under the scrip dividend scheme is:
174.45 pence for each new ordinary share.
This is equivalent to 1 new share for approximately 124.26 shares held prior to the ex-dividend date of 5 September 2019.
The Calculation Price is the average of the middle market quotations of a ConvaTec share, derived from the London Stock Exchange Daily Official List, for the five consecutive business days from 5 September to 11 September 2019 (inclusive).
The latest date for receipt of elections to participate in the scrip dividend scheme for this interim dividend is 23 September 2019. Shareholders must return their mandate form by 5pm (GMT) or otherwise input their CREST elections to be received by the Company's registrar, Computershare, by 3pm (GMT) on 23 September 2019. Elections received after this deadline will apply to subsequent dividends only. Unless revoked by you, your scrip dividend election will apply for all future dividends for which a scrip dividend is offered. Evergreen elections for CREST shareholders cannot be accepted and elections will revert to cash by default after the payment of each dividend.
Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.
TIMETABLE
Key dates in respect of the scrip dividend scheme for the interim dividend are:




Ex-dividend Date


   5 September 2019




Record Date


6 September 2019




Scrip calculation price determined


5-11 September 2019 (inclusive)




Scrip calculation price available and announced


12 September 2019




Mandate delivery deadline for Shares held in uncertificated form


3.00 p.m. on 23 September 2019




Mandate delivery deadline for Shares held in certificated form


5.00 p.m. on 23 September 2019




  Announcement of the total amount of new shares to be issued


                      27 September 2019




  Dividend payment date


                           17 October 2019




  Dispatch of statement in accordance with section 7 of Scheme


                           17 October 2019




Rules and share certificates, CREST accounts credited/updated,
and first day of dealings in New Shares
                                                                                                                                               
                                                  
Enquiries
 
Analysts, Investors and Media
 
John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435
Mark Reynolds, Director Investor Relations, ConvaTec                 +44 (0)7551 036 625
investorrelations@convatec.com
Alastair Elwen, Finsbury                                                                  +44 (0)207 251 3801
 
Legal Entity Identifier Code:   213800LS272L4FIDOH92
 
About ConvaTec
 
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
 
 
# # #
END
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DIVCKBDQQBKDCCD